Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

10.1016/S0140-6736(07)60917-9

10.1097/01.AOG.0000140687.51048.73

10.1186/1471-2334-2-1

10.1053/jinf.2000.0723

10.1016/j.jinf.2005.03.005

Rosenstock J, Polidori D, Zhao Y, et al. Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycemic control, lowers body weight, and improves beta-cell function in subjects with type 2 diabetes on background metformin. Poster presented at: 46th Annual Meeting of the European Association for the Study of Diabetes, 20–24 September 2010, Stockholm, Sweden

Rosenstock J, Aggarwal N, Polidori D, et al. for the Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8

10.1097/gme.0b013e3181acb9ed

10.1111/j.1479-828X.2001.tb01238.x

10.1007/s11908-010-0137-9

10.1111/j.1600-0897.2006.00450.x

10.2337/diacare.21.3.451

10.1016/S0140-6736(10)60407-2